Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical Performance of the Protecta ICD and CRT-D

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meeting one of the following criteria can be included in Phase I of the study:~  * Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D)~ * Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant)~* Patients meeting one of the following criteria can be included in Phase II of the study:~  * Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device~ * Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D~ * Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant~Exclusion Criteria:~* Patients with a mechanical tricuspid heart valve~* Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study~* Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients~* Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc)~* Patients anticipated not being able to complete the study~* Patients unwilling to provide written informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-chamber detetction (Type: EXPERIMENTAL): Patients implanted with a Protecta VR-ICD.
- Dual-chamber detection (Type: EXPERIMENTAL): Patients implanted with a Protecta DR-ICD or CRT-D.

Based on this trial design, predict the completion outcome and termination type (if applicable).